SCHEMBL12215329

SCHEMBL12215329

COc1ccc(-n2cccc2)c2[nH]cc(C(=O)C(C)=O)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CYP3A4 P08684 3/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ GAA P10253 3/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ CNR2 P34972 1/20 0.35
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C8 P10632 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2B6 P20813 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ MTNR1A P48039 2/20 0.32
▸ MTNR1B P49286 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12215321 0.85 AAK1 (0.41) CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6
SCHEMBL12215377 0.78 CYP3A4 (0.49) CYP2C9CYP3A4KMT2ACYP1A2CYP2C8
SCHEMBL12215320 0.78 CYP3A4 (0.41) CYP2C9L3MBTL1CYP3A4ALDH1A1KDM4E
SCHEMBL13555236 0.78 CYP3A4 (0.41) CYP2C9L3MBTL1CYP3A4ALDH1A1KDM4E
SCHEMBL12215330 0.78 CYP3A4 (0.41) CYP2C9L3MBTL1CYP3A4ALDH1A1KDM4E
SCHEMBL12215333 0.78 KDM4E (0.47) CYP2C9L3MBTL1CYP3A4ALDH1A1KDM4E
SCHEMBL12215433 0.74 ALDH1A1 (0.43) CYP2C9CYP3A4ALDH1A1KDM4EHPGD
SCHEMBL12215340 0.73 GAA (0.43) CYP2C9CYP3A4ALDH1A1KDM4EHPGD
SCHEMBL12215338 0.72 CLEC4M (0.47) CYP3A4KDM4EGAACYP1A2CYP2C19
SCHEMBL12215356 0.72 IMPDH2 (0.42) CYP2C9L3MBTL1CYP3A4ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039486-B2 Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-18 — — US disclosed
US-20080132516-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY 2008-06-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132516-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES IDO2, IDO1, INMT CYP2C9 888/4885L3MBTL1 4429/4885CYP3A4 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback